Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
CABOMETYX — EXELIXIS INC, approved 2025-10-09 (NDA208692).
60,320 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.